# RIGHT Choice (NCT03839823)

> Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03839823
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Breast Cancer
- Interventions: Docetaxel / Capecitabine; Capecitabine / Vinorelbine; Paclitaxel / Gemcitabine; Ribociclib; Letrozole OR Anastrozole; Goserelin
- Enrollment: 222
- Primary outcome: Progression-free Survival

## Commentary we found

- YouTube: 51
- Podcasts: 42
- X threads: 16

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=right-choice-nct03839823

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03839823", "email": "<work email>"}; the inbox owner confirms by the emailed link.